Oxytocin Versus, Sublingual Misoprostol in the Secondary Prevention of Postpartum Hemorrhage After Vaginal Delivery

• Status: Not yet recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

Researchers sought to see how oxytocin versus, sublingual misoprostol affected estimated and measured blood loss during vaginal delivery in women who had blood loss >300 ml .

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aswan University Hospital
• Treatments: Misoprostol; Oxytocin

Criteria

Inclusion Criteria:

• vaginal birth in women who had blood loss >300 ml

Exclusion Criteria:

• <37 weeks of pregnancy,

• genital tract injuries,

• coagulation deficit,

• hypertension, preeclampsia,

• cardiac, renal, or hepatic disease,

• epilepsy,